FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975743527> ?p ?o ?g. }

• W1975743527 endingPage "1185" @default.
• W1975743527 startingPage "1177" @default.
• W1975743527 abstract "Of the four prostaglandin (PG) E receptor subtypes (EP1-EP4), EP2 and EP4 have been proposed to mediate the anabolic action of PGE(2) on bone formation but comparative evaluation studies of EPs on bone formation do not necessarily share a common mechanism, implying that their additional features including downstream MAPK pathways may be beneficial to resolve this issue. We systematically assessed the roles of EPs in the rat calvaria (RC) cell culture model by using four selective EP agonists (EPAs). Consistent with relative expression levels of the respective receptors, multiple phenotypic traits of bone formation in vitro, including proliferation of nodule-associated cells, osteoblast marker expression and mineralized nodule formation were upregulated not only by PGE(2) but equally by EP2A and EP4A, but not by EP1A and EP3A. EP2A and EP4A were effective when cells were treated chronically or pulse-treated during nascent nodule formation. EP2A and EP4A equally stimulated the endogenous PGE(2) production, while EP2A caused a greater increase in cAMP production and c-Fos gene expression compared to EP4A. EP2A and EP4A activated predominantly p38 MAPK and ERK respectively, while c-Jun N-terminal kinase (JNK) was equally activated by both agonists. SB203580 (p38 MAPK inhibitor) blocked the PGE(2) effect on mineralized nodule formation, while U0126 (ERK inhibitor) and dicumarol (JNK inhibitor) were less effective. PGE(2)-dependent phosphorylation of the MAPKs was affected not only by protein kinase (PK)A and PKC inhibitors but also by adenylate cyclase and PKC activators. Co-treatment of RC cells with EP2A or EP4A and bone morphogenetic protein (BMP)2, whose effects on bone nodule formation is known to be, in part, mediated through the PKA and p38 MAPK pathways, resulted in an additive effect on mineralized nodule formation. Further, PGE(2), EP2A and EP4A did not increase BMP2/4 mRNA levels in RC cells, and EP2-induced phosphorylation of p38 MAPK was not eliminated by Noggin. These results suggest that, in the RC cell model, the anabolic actions of PGE(2) on mineralized nodule formation are mediated at least in part by activation of the EP2 and EP4 receptor subtype-specific MAPK pathways, independently of BMP signaling, in cells associated with nascent bone nodules." @default.
• W1975743527 created "2016-06-24" @default.
• W1975743527 creator A5006081238 @default.
• W1975743527 creator A5021926601 @default.
• W1975743527 creator A5031900884 @default.
• W1975743527 creator A5035505722 @default.
• W1975743527 creator A5064472711 @default.
• W1975743527 date "2009-06-01" @default.
• W1975743527 modified "2023-10-07" @default.
• W1975743527 title "EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures" @default.
• W1975743527 cites W1846149196 @default.
• W1975743527 cites W1967402039 @default.
• W1975743527 cites W1968306134 @default.
• W1975743527 cites W1982455287 @default.
• W1975743527 cites W1982883927 @default.
• W1975743527 cites W1984588551 @default.
• W1975743527 cites W1987381637 @default.
• W1975743527 cites W1992184028 @default.
• W1975743527 cites W1996424387 @default.
• W1975743527 cites W2002254327 @default.
• W1975743527 cites W2007362470 @default.
• W1975743527 cites W2014609002 @default.
• W1975743527 cites W2022308645 @default.
• W1975743527 cites W2023194934 @default.
• W1975743527 cites W2031400357 @default.
• W1975743527 cites W2032633863 @default.
• W1975743527 cites W2038370776 @default.
• W1975743527 cites W2039962739 @default.
• W1975743527 cites W2040800477 @default.
• W1975743527 cites W2044742025 @default.
• W1975743527 cites W2051066183 @default.
• W1975743527 cites W2056269123 @default.
• W1975743527 cites W2056376265 @default.
• W1975743527 cites W2058034672 @default.
• W1975743527 cites W2059134507 @default.
• W1975743527 cites W2062497599 @default.
• W1975743527 cites W2066578176 @default.
• W1975743527 cites W2070043197 @default.
• W1975743527 cites W2080694567 @default.
• W1975743527 cites W2081868490 @default.
• W1975743527 cites W2085733133 @default.
• W1975743527 cites W2089016492 @default.
• W1975743527 cites W2090589737 @default.
• W1975743527 cites W2092695803 @default.
• W1975743527 cites W2095049802 @default.
• W1975743527 cites W2099627744 @default.
• W1975743527 cites W2104682440 @default.
• W1975743527 cites W2107043674 @default.
• W1975743527 cites W2108783581 @default.
• W1975743527 cites W2113442798 @default.
• W1975743527 cites W2115293226 @default.
• W1975743527 cites W2119162416 @default.
• W1975743527 cites W2122427056 @default.
• W1975743527 cites W2123206983 @default.
• W1975743527 cites W2123692608 @default.
• W1975743527 cites W2129746956 @default.
• W1975743527 cites W2134678935 @default.
• W1975743527 cites W2141159170 @default.
• W1975743527 cites W2143030475 @default.
• W1975743527 cites W2148558073 @default.
• W1975743527 cites W2166629377 @default.
• W1975743527 cites W4230437325 @default.
• W1975743527 cites W4234150766 @default.
• W1975743527 doi "https://doi.org/10.1016/j.bone.2009.02.010" @default.
• W1975743527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19233324" @default.
• W1975743527 hasPublicationYear "2009" @default.
• W1975743527 type Work @default.
• W1975743527 sameAs 1975743527 @default.
• W1975743527 citedByCount "60" @default.
• W1975743527 countsByYear W19757435272012 @default.
• W1975743527 countsByYear W19757435272013 @default.
• W1975743527 countsByYear W19757435272014 @default.
• W1975743527 countsByYear W19757435272015 @default.
• W1975743527 countsByYear W19757435272016 @default.
• W1975743527 countsByYear W19757435272017 @default.
• W1975743527 countsByYear W19757435272018 @default.
• W1975743527 countsByYear W19757435272019 @default.
• W1975743527 countsByYear W19757435272020 @default.
• W1975743527 countsByYear W19757435272021 @default.
• W1975743527 countsByYear W19757435272022 @default.
• W1975743527 countsByYear W19757435272023 @default.
• W1975743527 crossrefType "journal-article" @default.
• W1975743527 hasAuthorship W1975743527A5006081238 @default.
• W1975743527 hasAuthorship W1975743527A5021926601 @default.
• W1975743527 hasAuthorship W1975743527A5031900884 @default.
• W1975743527 hasAuthorship W1975743527A5035505722 @default.
• W1975743527 hasAuthorship W1975743527A5064472711 @default.
• W1975743527 hasBestOaLocation W19757435272 @default.
• W1975743527 hasConcept C126322002 @default.
• W1975743527 hasConcept C134018914 @default.
• W1975743527 hasConcept C170493617 @default.
• W1975743527 hasConcept C184235292 @default.
• W1975743527 hasConcept C185592680 @default.
• W1975743527 hasConcept C195794163 @default.
• W1975743527 hasConcept C202751555 @default.
• W1975743527 hasConcept C2777198256 @default.
• W1975743527 hasConcept C2777956040 @default.
• W1975743527 hasConcept C2778260815 @default.

• next